This is HDAX
We are dedicated to bringing transformative therapies to patients – empowering them to embrace life to its fullest.

Our Story

Born out of the lab of Professor Patrick Gunning at the University of Toronto, a serial entrepreneur with a successful track record that includes Dunad, Dalriada Drug Discovery, and Janpix, HDAX Therapeutics was created with a foundation in translational science and a mission to advance revolutionary treatments.
Our entrepreneurial drug developers built the technology behind HDAX from a mere concept to distinct programs with therapeutical potential in neurology and cardiac diseases among others. With the support of world-class advisors and global accelerators, HDAX is well equipped with an extensive network, profound passion and unwavering tenacity to transform therapeutic outcomes for patients.

Our Mission

HDAX exists to deliver meaningful medicines for patients. We recognize the challenges with current HDAC6 targeting strategies, and are fundamentally reconceptualizing the way it is approached to unlock its full therapeutic potential and revolutionize patient outcomes. Our values serve as our inspiration to excel in our endeavours and never lose sight of why our work matters – to change patients’ lives.
Artboard 15 copy 3 1
Artboard 15 copy 3 1

Innovation

Artboard 15 copy 4 1
Artboard 15 copy 4 1

Collaboration

Artboard 15 copy 5 2
Artboard 15 copy 5 2

Integrity

Our Team

HDAX has a unique blend of experienced leaders and passionate founders equipped with scientific background and business expertise to lead the future of precision HDAC6 targeting for diseases with high unmet needs.

Leadership

Nabanita Nawar, PhD

CEO & Co-founder

Pimyupa Manaswiyoungkul, PhD

COO & Co-founder

Roman Fleck, PhD

Executive Chair

Founders

Professor Patrick Gunning, PhD

Co-Founder

Elvin de Araujo, PhD

Co-founder

Olasunkanmi Olaoye, PhD

Co-founder

Advisors

Professor Ahmet Hoke, PhD

Scientific and Clinical

Neal Muni, M.D., MSPH

Business and Strategy Advisor, Independent Board Member

Our Partners

HDAX has partnered with renowned investors, accelerators, and institutions who share our vision of a better treatment paradigm.
Berkley Skydeck 1
Facit 1
Mitacs 1
Ontario Bioscience 1
TIAP 1
University of Toronto 1
VitaDAO 1
Berkley Skydeck 1
Facit 1
Mitacs 1
Ontario Bioscience 1
TIAP 1
University of Toronto 1
VitaDAO 1
Plus backgrround 5 1

Do you share our vision?

Be the first to know our next discoveries.